CNO vs PRI: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
PRI is the larger of the two ($8.70B market cap): the incumbent the market prices for continued execution (10.40x forward earnings, beta 0.88). CNO is the smaller challenger ($5.06B), priced similarly on forward earnings (10.80x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CNO vs PRI: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CNO | PRI | What it tells you |
|---|---|---|---|
| Market cap | $5.06B | $8.70B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.80 | 10.40 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 18.93 | 11.35 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.81 | 0.88 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 85% of range | 54% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.96 | 3.46 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CNO and PRI affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNO and PRI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNO and PRI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does CNO Financial Group (CNO) do?
CNO Financial Group provides life and health insurance, annuities, and workforce benefits to middle-income and senior consumers across the United States. It reaches customers through a mix of career agents (Bankers Life), worksite and independent distribution (Washington National and Optavise), and direct-to-consumer channels (Colonial Penn, known for its television-advertised life policies). The company reports roughly 3.3 million policies and about $39 billion in total assets, and organizes its business around three main insurance segments plus a fee-based benefits arm.
What does Primerica (PRI) do?
Primerica sells simple term life insurance it underwrites itself, plus mutual funds, managed accounts, annuities, segregated funds and brokered mortgages that other firms manufacture. What makes the company unusual is the distribution: about 148,600 life-licensed independent representatives, most of them working part time and recruited from the same middle-income communities they sell into. Three segments carry the results. Term Life Insurance produced roughly $444 million of adjusted operating revenue and about $148 million of pre-tax income in the second quarter of 2026, a 21.3% segment margin off an in-force block built up over decades. Investment and Savings Products (ISP) produced about $361 million of revenue and $104 million of pre-tax income on record quarterly sales of roughly $4.4 billion. Corporate and Other Distributed Products, which includes mortgage brokerage and net investment income, adds a small remainder. The Senior Health segment, built around the e-TeleQuote Medicare brokerage acquired in 2021, was exited in 2024 and no longer appears in the segment tables.
CNO vs PRI: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CNO drivers: Middle-income and senior market focus; Consistent sales and earnings momentum.
- PRI drivers: The investment and savings flywheel; The in-force term life book as the cash engine.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNO carries the typical risks of a life and health insurer. For PRI, the clearest risk is the distribution model itself, because a life-licensed force that shrinks 3% a year eventually shows up in issued policies, then in in-force premium, then in Term Life earnings.
CNO or PRI: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CNO if you believe its drivers more; PRI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNO and PRI guides.
CNO vs PRI: the full fundamentals
CNO. CNO still trades at a modest forward earnings multiple of about 11 times relative to the broader market, consistent with its profile as a mature, mid-cap insurer, even after a roughly 30% gain in 2026. The trailing GAAP P/E of about 19 looks higher because reported net income includes investment and reserve swings that operating earnings exclude. Third quarter results arrive October 29, 2026, with consensus operating EPS of about $1.10 on roughly $1.01 billion of revenue.
PRI. At about $283.54 on October 16, 2026, PRI trades near 11.4 times trailing earnings of about $24.90 and 10.4 times forward estimates, a little cheaper than in August after the stock's three-month pullback. Price to book is about 3.5 times, a premium that reflects reported return on equity of 32.1% rather than an insurer-style balance sheet story. Screeners sometimes carry a stale Senior Health segment or a depressed 2024 earnings base, since the e-TeleQuote exit pushed second-quarter 2024 net income to roughly $1 million; the FY2025 figures of $3.29 billion revenue and $22.91 diluted EPS are the cleaner comparison.
Headline figures (approximate, October 2026): CNO shows market cap ~$5.1B, revenue (ttm) ~$4.65B, +11.6% YoY in Q2 2026, net income (ttm) ~$280M, ~6% net margin, operating eps (q2 2026) ~$1.26 vs ~$0.97 consensus; PRI shows revenue (ttm) ~$3.49B, up ~8.7% year over year in Q2 2026, net income (ttm) ~$794M (~23% net margin), diluted eps (ttm) ~$24.90; 2026 consensus ~$25.27, 2027 ~$27.22, latest quarter (q2 2026) Adjusted operating EPS ~$6.41 vs ~$6.01 estimate; revenue ~$865M.
The bottom line: CNO vs PRI
CNO and PRI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNO and PRI exposure against your real portfolio. It is not an investment adviser.
Wondering how CNO or PRI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in CNO Financial Group with AI
Connect the broker you already use and ask Walnut's AI how CNO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CNO and PRI?
+
CNO Financial Group provides life and health insurance, annuities, and workforce benefits to middle-income and senior consumers across the United States. Primerica sells simple term life insurance it underwrites itself, plus mutual funds, managed accounts, annuities, segregated funds and brokered mortgages that other firms manufacture. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CNO or PRI the better stock?
+
Neither is universally better. PRI is the larger incumbent; CNO is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CNO or PRI?
+
On forward P/E (as of October 2026), CNO trades at 10.80x and PRI at 10.40x, so PRI is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CNO and PRI?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CNO vs PRI?
+
CNO: CNO carries the typical risks of a life and health insurer. Its investment portfolio is exposed to credit losses, and prolonged low or sharply changing interest rates can pressure spread income and reserve adequacy; rising yields also cut the market value of bonds already held. Legacy long-term-care insurance blocks can require reserve strengthening if claims or assumptions worsen. Quarterly GAAP earnings are volatile (net income swung from about $23 million in Q3 2025 to $126 million in Q2 2026), and analysts expect third quarter operating EPS of about $1.10, below the year-earlier $1.29. Margin compression, adverse mortality or morbidity trends, and regulatory or reserving changes can weigh on earnings. After a roughly 42% one-year gain the stock trades near the analyst mean target of about $54.75 (consensus rating hold), and as a mid-cap insurer it can be more sensitive to sentiment shifts than larger, more diversified peers. PRI: The clearest risk is the distribution model itself, because a life-licensed force that shrinks 3% a year eventually shows up in issued policies, then in in-force premium, then in Term Life earnings. ISP earnings are levered to equity market levels through asset-based fees, so a drawdown in client asset values would compress the segment that is currently carrying the growth story. Regulatory exposure is broad and specific to this structure: state insurance regulation, SEC and FINRA oversight of the broker-dealer, suitability and fiduciary standards on investment products, and the ongoing question of independent-contractor classification for a sales force of this size. Term life results also depend on mortality and persistency assumptions and on the reinsurance counterparties behind roughly half of ceded premiums. Canadian operations add currency translation, and the ISP business depends on third-party fund managers and annuity providers whose products Primerica does not control. Market sentiment adds its own swing: the stock fell about 8% in the months after a quarter that beat estimates, a reminder that the multiple can compress on the recruiting and licensing data even when earnings come in ahead.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNO or PRI; figures are approximate and dated (as of October 2026). Verify current data before investing.